Asian Stocks Rally as Nvidia Earnings Boost Tech Shares, Samsung Jumps on Wage Deal 
SoftBank Shares Surge as OpenAI IPO Buzz and SB Energy Filing Boost AI Optimism 
Anthropic Revenue Surge Signals Strong AI Market Momentum in 2026 
H.B. Fuller Eyes Advanced Medical Solutions in Potential £600M Takeover Deal 
Trump to Swear In Kevin Warsh as New Federal Reserve Chair Amid Inflation Concerns 
Asian Stocks Slide Ahead of Nvidia Earnings as Tech Shares Tumble 
Samsung Union Confirms 18-Day Strike After Failed Wage Talks 
PDG Explores $1 Billion Sale of China Data Center Assets 
OpenAI Expands Globally with First Overseas AI Lab in Singapore 
Tencent Shares Jump 4% as AI Models Move Toward Paid Commercial Services 
SpaceX Starship V3 Test Flight Boosts IPO Momentum Ahead of Historic Market Debut 
Lam Research Expands AI-Powered Semiconductor Tools and Arizona Operations 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Japan Airlines Signs 10-Year Boeing 787 Maintenance Deal With GE Aerospace 
US Economy Fueled by AI Investment Faces Rising Risks Ahead of Fed Meeting 
Gold Prices Slip as Iran Conflict and Fed Rate Hike Fears Weigh on Market Sentiment 
Goldman Sachs to Pay $500M in 1MDB Shareholder Fraud Settlement 
Merck & Co Inc. gets the green light from the Japanese health ministry for its COVID-19 anti-viral pill. The health officials recommended the approval of the said medicine late last week.
The approval of the Merck coronavirus pill is said to be part of the country’s Prime Minister Fumio Kishida’s plan to introduce and distribute new treatments by the end of the year as the growing cases of Omicron variant infection is becoming a very serious concern.
According to Inquirer.net, the committee’s decision has led to the shipments of around 200,000 doses starting this weekend. This is just the preparation and start of the deliveries as per the announcement of the country’s prime minister.
“I am convinced the distribution of this drug is a major step forward for our nation’s COVID–19 handling,” Shigeyuki Goto, Japan’s health minister, told the press after the announcement of the panel’s approval of Merck’s COVID-19 treatment pill.
He added that some of the country’s pharmacies and medical institutions are expected to begin receiving the medicine as early as next Monday. Moreover, it was said that Japan is really laying bets on oral treatments to prevent cases of severe infections and deaths should a sixth wave of the pandemic arise.
Based on the report, Japan agreed to pay $1.2 billion to Merck and its partner Ridgeback Biotherapeutics for the shipment of 1.6 million courses of molnupiravir. PM Kishida also said last week, the government signed a deal for two million doses of another anti-viral treatment pill and this was developed by Pfizer.
In the U.S., health regulators also authorized the use of the Merck pill for some high-risk adult patients. Many countries are now rushing to purchase the said Merck’s molnupiravir due to promising results during trials.
“As a single oral medicine that can be taken at home, early treatment with molnupiravir significantly reduced the risk of hospitalization or death in patients at high risk for progressing to severe COVID-19,” Merck research laboratories president, Dr. Dean Y. Li, said in a press release. “Importantly for patients, there were markedly fewer deaths among those taking molnupiravir in our clinical study and we believe that it will be a critical addition to the measures available to help curb the impact of COVID-19 on patients, healthcare systems, and public health in Japan.”
